{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2023_00029047", "CSN": null, "TRF": "ORD_1619484_01", "MRN": "24127524", "PhysicianId": "109266", "NPI": null}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1313963", "clinicalId": "1315310", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1619484_01", "SampleName": "US1545611.01", "Version": "0", "Sample": {"FM_Id": "ORD_1619484_01", "SampleId": "US1545611.01", "BlockId": "S111-70820A", "TRFNumber": "ORD_1619484_01", "TestType": "FoundationOne CDx             ", "SpecFormat": "FFPE", "ReceivedDate": "2023_04_28", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}]}, "TumorPurity": "30", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "M112-10097", "MRN": "24127524", "FullName": "\u9ad8\u777f\u79b9", "FirstName": "Jui Yu", "LastName": "Kao", "SubmittedDiagnosis": "Liver angiosarcoma", "Gender": "Male", "DOB": "1987_11_27", "OrderingMD": "\u984f\u53a5\u5168", "OrderingMDId": "109266", "Pathologist": "\u9673\u5fd7\u5b78", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Liver", "CollDate": "2022_06_07", "ReceivedDate": "2023-05-11 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Sarcoma"}, "PertinentNegatives": null, "Summaries": {"alterationCount": "10", "clinicalTrialCount": "0", "resistiveCount": "0", "sensitizingCount": "0"}, "VariantProperties": {"VariantProperty": [{"geneName": "ALK", "isVUS": "true", "variantName": "W1320R"}, {"geneName": "ERBB4", "isVUS": "true", "variantName": "rearrangement"}, {"geneName": "MAP3K1", "isVUS": "true", "variantName": "G51D"}, {"geneName": "MSH3", "isVUS": "true", "variantName": "A58V"}, {"geneName": "ROS1", "isVUS": "true", "variantName": "I537K"}, {"geneName": "SPEN", "isVUS": "true", "variantName": "S2306del"}, {"geneName": "TSC1", "isVUS": "true", "variantName": "Q654E"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "Cannot Be Determined", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Cannot Be Determined"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). The level of MSI in this sample could not be determined with confidence. Depending on the clinical context, MSI testing of an alternate sample or by another methodology could be considered. In a computational analysis of paired tumor and normal sarcomas in the TCGA dataset, of which 25% were liposarcomas, only 0.8% (2/255) of samples were MSI_high (MSI_H) (Bonneville et al., 2017; 29850653). However, reports of MSI in sarcomas in the literature are conflicting and varied due to substantial heterogeneity, lack of consensus on the markers and methods used for MSI assessment, and small sample size in most studies (Monument et al., 2012; 23401795). In these smaller studies of soft tissue sarcoma, reports of MSI at any level have been rare, with the highest incidences between 11% (2/18) to 25% (10/40) of cases (Wooster al., 1994; 8162069, Kawaguchi et al., 2005; 15643505, Saito et al., 2003; 14562278, Suwa et al., 1999; 10370164, Garcia et al., 2006; 16619000, Aue et al., 1998; 9689926). In one study, MSI was reported to occur more frequently in high_grade soft tissue sarcomas compared with lower grade (Ruci\u0144ska et al., 2005; 15668629). However, published data investigating the prognostic implications of MSI in sarcoma are limited (PubMed, Jan 2023). On the basis of clinical evidence in multiple solid tumor types, microsatellite instability (MSI) and associated increased tumor mutational burden (TMB) (Jass, 2007; 17204026, Lal et al., 2015; 25949894) may predict sensitivity to immune checkpoint inhibitors, including the approved PD_1_targeting agents cemiplimab, dostarlimab, nivolumab (alone or in combination with ipilimumab), retifanlimab, and pembrolizumab (Overman et al., 2017; 28734759, Overman et al., 2018; 29355075, Overman et al., 2019; ASCO Abstract 635, Shitara et al., 2022; 35322232, Andre et al., 2022; ASCO GI Abstract 244, Lipson et al., 2013; 23169436, Le et al., 2015; 26028255, Rizvi et al., 2015; 25765070, Oaknin et al., 2020; 33001143, Berton et al., 2021; SITC Abstract 956), as well as PD_L1_targeting agents atezolizumab, avelumab, and durvalumab (alone or in combination with tremelimumab) (Hochster et al., 2017; ASCO Abstract 673, Fleming et al., 2018; ASCO Abstract 5585, Bang et al., 2018; ASCO Abstract 92, Pietrantonio et al., 2023; ASCO GI Abstract 358, Lee et al., 2023; ASCO GI abstract 401, Rubinstein et al., 2022; 36512912, Marie et al., 2021; 33811152). As the MSI status of this tumor is unknown, the relevance of these therapeutic approaches is unclear.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "TP53", "Include": "true", "Alterations": {"Alteration": {"Name": "rearrangement intron 7", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "rearrangement intron 7"}}, "Interpretation": "Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers (Brown et al., 2009; 19935675). Alterations such as seen here may disrupt TP53 function or expression (Joerger and Fersht, 2008; 18410249, Kato et al., 2003; 12826609, Kamada et al., 2011; 20978130, Zerdoumi et al., 2017; 28472496, Yamada et al., 2007; 17690113). TP53 mutation has been cited at various incidences in studies of angiosarcoma, which may reflect small sample sizes or differences in tumor site examined (Naka et al., 1997; 9185695, Santi et al., 2011; 21323968, Italiano et al., 2012; 22648906, Zietz et al., 1998; 9811333, Soini et al., 1995; 7586214, Painter et al., 2020; 32042194). Expression of p53, which is typically associated with non_functional p53, has been reported in 49%_100% of patients with angiosarcoma, and has been correlated with poor prognosis (Italiano et al., 2012; 22648906, Chen et al., 2008; 18700251). There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib (Hirai et al., 2010; 20107315, Bridges et al., 2011; 21799033, Rajeshkumar et al., 2011; 21389100, Osman et al., 2015; 25504633) or p53 gene therapy such as SGT53 (Xu et al., 2002; 12489850, Xu et al., 2001; 11713371, Camp et al., 2013; 23470564, Kim et al., 2015; 25240597, Pirollo et al., 2016; 27357628, Leung et al., 2021; ASCO Abstract 4139). In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% and SDs in 53% of patients with solid tumors; the response rate was 21% (4/19) for patients with TP53 mutations versus 12% (4/33) for patients who were TP53 wildtype (Leijen et al., 2016; 27601554). A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 32% (30/94, 3 CR) ORR and a 73% (69/94) DCR for patients with platinum_refractory TP53_mutated ovarian, Fallopian tube, or peritoneal cancer (Moore et al., 2019; ASCO Abstract 5513). A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 43% (9/21, 1 CR) ORR and a 76% (16/21) DCR for patients with platinum_refractory TP53_mutated ovarian cancer (Leijen et al., 2016; 27998224). The combination of adavosertib with paclitaxel and carboplatin for patients with TP53_mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone (Oza et al., 2015; ASCO Abstract 5506). In the Phase 2 VIKTORY trial, patients with TP53_mutated metastatic and/or recurrent gastric cancer experienced a 24% (6/25) ORR with adavosertib combined with paclitaxel (Lee et al., 2019; 31315834). A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71% (5/7) response rate for patients with TP53 alterations (Mendez et al., 2018; 29535125). The Phase 2 FOCUS4_C trial for patients with TP53_ and RAS_mutated colorectal cancer reported improvement in PFS (3.61 vs. 1.87 months, HR=0.35, p=0.0022), but not OS (14.0 vs 12.8 months, p=0.93), following adavosertib treatment compared with active monitoring (Seligmann et al., 2021; 34538072). In a Phase 1b clinical trial of SGT_53 in combination with docetaxel for patients with solid tumors, 75% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage (Pirollo et al., 2016; 27357628). Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li_Fraumeni syndrome and the early onset of many cancers (Bougeard et al., 2015; 26014290, Sorrell et al., 2013; 23355100, Nichols et al., 2001; 11219776), including sarcomas (Kleihues et al., 1997; 9006316, Gonzalez et al., 2009; 19204208). Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000 (Lalloo et al., 2003; 12672316) to 1:20,000 (Gonzalez et al., 2009; 19204208). For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30 (Mandelker et al., 2019; 31050713). In the appropriate clinical context, germline testing of TP53 is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Mutation Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "Cannot Be Determined", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Cannot Be Determined"}}, "Interpretation": "Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). Elevated TMB has been reported to be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors in multiple solid tumor types (Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947, Goodman et al., 2017; 28835386, Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915). However, the TMB level in this sample could not be determined with confidence. Angiosarcomas of the head, neck, face, or scalp were associated with a high TMB (median of 20.7 Muts/Mb, >10 Muts/Mb in 9/12 samples) and a dominant ultraviolet light exposure mutational signature in one study (Painter et al., 2020; 32042194). In contrast, angiosarcomas of other sites, including cutaneous radiation_associated or breast angiosarcomas (median TMB of 3.7 and 1.7 Muts/Mb, respectively) had lower TMB (Painter et al., 2020; 32042194). Soft tissue sarcomas harbor a median tumor mutational burden (TMB) of 2.4_2.5 mutations per megabase (muts/Mb), with angiosarcoma (up to 15%) and malignant peripheral nerve sheath tumor (up to 11%) having the highest percentage of cases with high TMB (Gounder et al., 2022; 35705558, FMI_Chalmers et al., 2017; 28420421). In a study, 3.9% of soft tissue sarcoma samples analyzed harbor TMB \u226510 muts/Mb (Gounder et al., 2022; 35705558); in addition, increased mutational burden has been reported in undifferentiated pleomorphic sarcomas as compared with Ewing sarcomas or rhabdomyosarcomas (Lim et al., 2015; 26330427, Brohl et al., 2014; 25010205, Chen et al., 2013; 24332040). Published data investigating the prognostic implications of tissue TMB in sarcoma are conflicting (PubMed, Feb 2023). High tissue TMB was associated with improved PFS and metastasis_free survival in a study of undifferentiated sarcomas (Steele et al., 2019; 30889380), but with reduced survival in a study of patients with rhabdomyosarcoma (Casey et al., 2020; 31699828). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In multiple pan_tumor studies, increased tissue tumor mutational burden (TMB) was associated with sensitivity to immune checkpoint inhibitors (Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947, Ott et al., 2019; 30557521, Cristescu et al., 2022; 35101941, Friedman et al., 2022; 34876409, Sturgill et al., 2022; 35274716). In the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors, significant improvement in ORR was observed for patients with TMB \u226510 Muts/Mb (as measured by this assay) compared with those with TMB <10 Muts/Mb in a large cohort that included multiple tumor types (Marabelle et al., 2020; 32919526); similar findings were observed in the KEYNOTE 028 and 012 trials (Cristescu et al., 2018; 30309915). At the same TMB cutpoint, retrospective analysis of patients with solid tumors treated with any checkpoint inhibitor identified that tissue TMB scores \u2265 10 Muts/Mb were associated with prolonged time to treatment failure compared with scores <10 muts/Mb (HR=0.68) (Sturgill et al., 2022; 35274716). For patients with solid tumors treated with nivolumab plus ipilimumab in the CheckMate 848 trial, improved responses were observed in patients with a tissue TMB \u2265 10 Muts/Mb independent of blood TMB at any cutpoint in matched samples (Schenker at al., 2022; AACR Abstract 7845). However, support for higher TMB thresholds and efficacy was observed in the prospective Phase 2 MyPathway trial of atezolizumab for patients with pan_solid tumors, where improved ORR and DCR was seen in patients with TMB \u2265 16 Muts/Mb than those with TMB \u2265 10 and <16 Muts/Mb (Friedman et al., 2022; 34876409). Similarly, analyses across several solid tumor types reported that patients with higher TMB (defined as \u226516_20 Muts/Mb) achieved greater clinical benefit from PD_1 or PD_L1_targeting monotherapy compared with patients with higher TMB treated with chemotherapy (Legrand et al., 2018; ASCO Abstract 12000) or those with lower TMB treated with PD_1 or PD_L1_targeting agents (Goodman et al., 2017; 28835386). As the TMB status of this tumor cannot be determined with confidence, the benefit of these therapeutic approaches is unclear.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": null, "References": {"Reference": [{"number": "0", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "1", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "2", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "3", "ReferenceId": "29850653", "FullCitation": "Bonneville R, et al. JCO Precis Oncol (2017) pmid: 29850653", "Include": "true"}, {"number": "4", "ReferenceId": "23401795", "FullCitation": "Monument MJ, et al. ISRN Oncol (2012) pmid: 23401795", "Include": "true"}, {"number": "5", "ReferenceId": "8162069", "FullCitation": "Wooster R, et al. Nat. Genet. (1994) pmid: 8162069", "Include": "true"}, {"number": "6", "ReferenceId": "15643505", "FullCitation": "Kawaguchi K, et al. Oncol. Rep. (2005) pmid: 15643505", "Include": "true"}, {"number": "7", "ReferenceId": "14562278", "FullCitation": "Saito T, et al. Hum. Pathol. (2003) pmid: 14562278", "Include": "true"}, {"number": "8", "ReferenceId": "10370164", "FullCitation": "Suwa K, et al. J Orthop Sci (1999) pmid: 10370164", "Include": "true"}, {"number": "9", "ReferenceId": "16619000", "FullCitation": "Garcia JJ, et al. Mod. Pathol. (2006) pmid: 16619000", "Include": "true"}, {"number": "10", "ReferenceId": "9689926", "FullCitation": "Aue G, et al. Cancer Genet. Cytogenet. (1998) pmid: 9689926", "Include": "true"}, {"number": "11", "ReferenceId": "15668629", "FullCitation": "Ruci\u0144ska M, et al. Med. Sci. Monit. (2005) pmid: 15668629", "Include": "true"}, {"number": "12", "ReferenceId": "17204026", "FullCitation": "Histopathology (2007) pmid: 17204026", "Include": "true"}, {"number": "13", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "14", "ReferenceId": "28734759", "FullCitation": "Overman MJ, et al. Lancet Oncol. (2017) pmid: 28734759", "Include": "true"}, {"number": "15", "ReferenceId": "29355075", "FullCitation": "Overman MJ, et al. J. Clin. Oncol. (2018) pmid: 29355075", "Include": "true"}, {"number": "16", "ReferenceId": "35322232", "FullCitation": "Shitara K, et al. Nature (2022) pmid: 35322232", "Include": "true"}, {"number": "17", "ReferenceId": "23169436", "FullCitation": "Lipson EJ, et al. Clin. Cancer Res. (2013) pmid: 23169436", "Include": "true"}, {"number": "18", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "19", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "20", "ReferenceId": "33001143", "FullCitation": "Oaknin A, et al. JAMA Oncol (2020) pmid: 33001143", "Include": "true"}, {"number": "21", "ReferenceId": "36512912", "FullCitation": "Rubinstein MM, et al. Gynecol Oncol (2022) pmid: 36512912", "Include": "true"}, {"number": "22", "ReferenceId": "33811152", "FullCitation": "Kanikarla Marie P, et al. Clin Cancer Res (2021) pmid: 33811152", "Include": "true"}, {"number": "23", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "24", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "25", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "26", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "27", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "28", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "29", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "30", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "31", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "32", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "33", "ReferenceId": "32919526", "FullCitation": "Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526", "Include": "true"}, {"number": "34", "ReferenceId": "31405947", "FullCitation": "Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947", "Include": "true"}, {"number": "35", "ReferenceId": "28835386", "FullCitation": "Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386", "Include": "true"}, {"number": "36", "ReferenceId": "30309915", "FullCitation": "Cristescu R, et al. Science (2018) pmid: 30309915", "Include": "true"}, {"number": "37", "ReferenceId": "32042194", "FullCitation": "Painter CA, et al. Nat. Med. (2020) pmid: 32042194", "Include": "true"}, {"number": "38", "ReferenceId": "35705558", "FullCitation": "Gounder MM, et al. Nat Commun (2022) pmid: 35705558", "Include": "true"}, {"number": "39", "ReferenceId": "28420421", "FullCitation": "Chalmers ZR, et al. Genome Med (2017) pmid: 28420421", "Include": "true"}, {"number": "40", "ReferenceId": "26330427", "FullCitation": "Lim J, et al. Clin. Cancer Res. (2015) pmid: 26330427", "Include": "true"}, {"number": "41", "ReferenceId": "25010205", "FullCitation": "Brohl AS, et al. PLoS Genet. (2014) pmid: 25010205", "Include": "true"}, {"number": "42", "ReferenceId": "24332040", "FullCitation": "Chen X, et al. Cancer Cell (2013) pmid: 24332040", "Include": "true"}, {"number": "43", "ReferenceId": "30889380", "FullCitation": "Steele CD, et al. Cancer Cell (2019) pmid: 30889380", "Include": "true"}, {"number": "44", "ReferenceId": "31699828", "FullCitation": "Casey DL, et al. Clin Cancer Res (2020) pmid: 31699828", "Include": "true"}, {"number": "45", "ReferenceId": "30643254", "FullCitation": "Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254", "Include": "true"}, {"number": "46", "ReferenceId": "30785829", "FullCitation": "Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829", "Include": "true"}, {"number": "47", "ReferenceId": "29658845", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845", "Include": "true"}, {"number": "48", "ReferenceId": "29657128", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128", "Include": "true"}, {"number": "49", "ReferenceId": "29731394", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394", "Include": "true"}, {"number": "50", "ReferenceId": "33558721", "FullCitation": "Rozeman EA, et al. Nat Med (2021) pmid: 33558721", "Include": "true"}, {"number": "51", "ReferenceId": "32916128", "FullCitation": "Sharma P, et al. Cancer Cell (2020) pmid: 32916128", "Include": "true"}, {"number": "52", "ReferenceId": "30557521", "FullCitation": "Ott PA, et al. J. Clin. Oncol. (2019) pmid: 30557521", "Include": "true"}, {"number": "53", "ReferenceId": "35101941", "FullCitation": "Cristescu R, et al. J Immunother Cancer (2022) pmid: 35101941", "Include": "true"}, {"number": "54", "ReferenceId": "34876409", "FullCitation": "Friedman CF, et al. Cancer Discov (2022) pmid: 34876409", "Include": "true"}, {"number": "55", "ReferenceId": "35274716", "FullCitation": "Sturgill EG, et al. Oncologist (2022) pmid: 35274716", "Include": "true"}, {"number": "56", "ReferenceId": "19935675", "FullCitation": "Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675", "Include": "true"}, {"number": "57", "ReferenceId": "18410249", "FullCitation": "Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249", "Include": "true"}, {"number": "58", "ReferenceId": "12826609", "FullCitation": "Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609", "Include": "true"}, {"number": "59", "ReferenceId": "20978130", "FullCitation": "Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130", "Include": "true"}, {"number": "60", "ReferenceId": "28472496", "FullCitation": "Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496", "Include": "true"}, {"number": "61", "ReferenceId": "17690113", "FullCitation": "Yamada H, et al. Carcinogenesis (2007) pmid: 17690113", "Include": "true"}, {"number": "62", "ReferenceId": "9185695", "FullCitation": "Naka N, et al. Int. J. Cancer (1997) pmid: 9185695", "Include": "true"}, {"number": "63", "ReferenceId": "21323968", "FullCitation": "Santi R, et al. Histopathology (2011) pmid: 21323968", "Include": "true"}, {"number": "64", "ReferenceId": "22648906", "FullCitation": "Italiano A, et al. Cancer (2012) pmid: 22648906", "Include": "true"}, {"number": "65", "ReferenceId": "9811333", "FullCitation": "Zietz C, et al. Am J Pathol (1998) pmid: 9811333", "Include": "true"}, {"number": "66", "ReferenceId": "7586214", "FullCitation": "Soini Y, et al. Carcinogenesis (1995) pmid: 7586214", "Include": "true"}, {"number": "67", "ReferenceId": "18700251", "FullCitation": "Chen SY, et al. J. Cutan. Pathol. (2008) pmid: 18700251", "Include": "true"}, {"number": "68", "ReferenceId": "20107315", "FullCitation": "Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315", "Include": "true"}, {"number": "69", "ReferenceId": "21799033", "FullCitation": "Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033", "Include": "true"}, {"number": "70", "ReferenceId": "21389100", "FullCitation": "Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100", "Include": "true"}, {"number": "71", "ReferenceId": "25504633", "FullCitation": "Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633", "Include": "true"}, {"number": "72", "ReferenceId": "12489850", "FullCitation": "Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850", "Include": "true"}, {"number": "73", "ReferenceId": "11713371", "FullCitation": "Xu L, et al. Mol. Med. (2001) pmid: 11713371", "Include": "true"}, {"number": "74", "ReferenceId": "23470564", "FullCitation": "Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564", "Include": "true"}, {"number": "75", "ReferenceId": "25240597", "FullCitation": "Kim SS, et al. Nanomedicine (2015) pmid: 25240597", "Include": "true"}, {"number": "76", "ReferenceId": "27357628", "FullCitation": "Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628", "Include": "true"}, {"number": "77", "ReferenceId": "27601554", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554", "Include": "true"}, {"number": "78", "ReferenceId": "27998224", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224", "Include": "true"}, {"number": "79", "ReferenceId": "31315834", "FullCitation": "Lee J, et al. Cancer Discov (2019) pmid: 31315834", "Include": "true"}, {"number": "80", "ReferenceId": "29535125", "FullCitation": "M\u00e9ndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125", "Include": "true"}, {"number": "81", "ReferenceId": "34538072", "FullCitation": "Seligmann JF, et al. J Clin Oncol (2021) pmid: 34538072", "Include": "true"}, {"number": "82", "ReferenceId": "26014290", "FullCitation": "Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290", "Include": "true"}, {"number": "83", "ReferenceId": "23355100", "FullCitation": "Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100", "Include": "true"}, {"number": "84", "ReferenceId": "11219776", "FullCitation": "Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776", "Include": "true"}, {"number": "85", "ReferenceId": "9006316", "FullCitation": "Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316", "Include": "true"}, {"number": "86", "ReferenceId": "19204208", "FullCitation": "Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208", "Include": "true"}, {"number": "87", "ReferenceId": "12672316", "FullCitation": "Lalloo F, et al. Lancet (2003) pmid: 12672316", "Include": "true"}, {"number": "88", "ReferenceId": "31050713", "FullCitation": "Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2023_05_07 15:31:44", "OpName": "Douglas A. Mata, MD, MPH | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Douglas A. Mata, MD, MPH | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "424x"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "1 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "Units Not Reported"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "LIVER", "disease_ontology": "Liver angiosarcoma", "flowcell_analysis": "2000028929", "gender": "male", "pathology_diagnosis": "Angiosarcoma", "percent_tumor_nuclei": "30", "pipeline_version": "v3.22.0", "purity_assessment": "19.07", "specimen": "ORD_1619484_01*US1545611.01", "study": "CLINICAL_F1CDx v2", "test_request": "ORD_1619484_01", "test_type": "FoundationOneDx", "tissue_of_origin": "Liver", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "DX2", "mean_exon_depth": "424.68", "name": "SQ_US1545611.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Qualified"}, "short_variants": {"short_variant": [{"allele_fraction": "0.4504", "cds_effect": "6915_6917delCAG", "depth": "353", "equivocal": "false", "functional_effect": "nonframeshift", "gene": "SPEN", "percent_reads": "45.04", "position": "chr1:16259649", "protein_effect": "S2306del", "status": "unknown", "strand": "+", "transcript": "NM_015001", "dna_evidence": {"sample": "SQ_US1545611.01_1"}}, {"allele_fraction": "0.51", "cds_effect": "173C>T", "depth": "200", "equivocal": "false", "functional_effect": "missense", "gene": "MSH3", "percent_reads": "51.0", "position": "chr5:79950719", "protein_effect": "A58V", "status": "unknown", "strand": "+", "transcript": "NM_002439", "dna_evidence": {"sample": "SQ_US1545611.01_1"}}, {"allele_fraction": "0.1746", "cds_effect": "1610T>A", "depth": "544", "equivocal": "false", "functional_effect": "missense", "gene": "ROS1", "percent_reads": "17.46", "position": "chr6:117710662", "protein_effect": "I537K", "status": "unknown", "strand": "_", "transcript": "NM_002944", "dna_evidence": {"sample": "SQ_US1545611.01_1"}}, {"allele_fraction": "0.0972", "cds_effect": "3958T>C", "depth": "463", "equivocal": "false", "functional_effect": "missense", "gene": "ALK", "percent_reads": "9.72", "position": "chr2:29420523", "protein_effect": "W1320R", "status": "unknown", "strand": "_", "transcript": "NM_004304", "dna_evidence": {"sample": "SQ_US1545611.01_1"}}, {"allele_fraction": "0.5556", "cds_effect": "152G>A", "depth": "171", "equivocal": "false", "functional_effect": "missense", "gene": "MAP3K1", "percent_reads": "55.56", "position": "chr5:56111552", "protein_effect": "G51D", "status": "unknown", "strand": "+", "transcript": "NM_005921", "dna_evidence": {"sample": "SQ_US1545611.01_1"}}, {"allele_fraction": "0.5394", "cds_effect": "1960C>G", "depth": "406", "equivocal": "false", "functional_effect": "missense", "gene": "TSC1", "percent_reads": "53.94", "position": "chr9:135781005", "protein_effect": "Q654E", "status": "unknown", "strand": "_", "transcript": "NM_000368", "dna_evidence": {"sample": "SQ_US1545611.01_1"}}]}, "copy_number_alterations": null, "rearrangements": {"rearrangement": [{"allele_fraction": "0.0717", "description": "ERBB4(NM_005235) rearrangement intron 22", "equivocal": "false", "in_frame": "unknown", "other_gene": "SCIN", "percent_reads": "7.17", "pos1": "chr2:212293049", "pos2": "chr7:12665886", "status": "unknown", "supporting_read_pairs": "39", "targeted_gene": "ERBB4", "type": "rearrangement", "dna_evidence": {"sample": "SQ_US1545611.01_1"}}, {"allele_fraction": "0.0596", "description": "TP53(NM_000546) rearrangement intron 7", "equivocal": "false", "in_frame": "unknown", "other_gene": "AP3B1", "percent_reads": "5.96", "pos1": "chr17:7577284", "pos2": "chr5:77361467", "status": "likely", "supporting_read_pairs": "24", "targeted_gene": "TP53", "type": "truncation", "dna_evidence": {"sample": "SQ_US1545611.01_1"}}]}, "biomarkers": {"microsatellite_instability": {"status": "unknown"}, "tumor_mutation_burden": {"score": "1.21", "status": "unknown", "unit": "mutations_per_megabase"}}, "non_human_content": null}}}}